Development of flexible-heteroarotinoids for kidney cancer - Wikidata - wikimedia - TriplyDB

Development of flexible-heteroarotinoids for kidney cancer

Development of flexible-heteroarotinoids for kidney cancer

http://www.wikidata.org/entity/Q33926659

about

NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis.Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen.Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity.Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents.SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs.IR- Role of adaptor protein p66Shc in renal pathologies.Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2.

P2860

Q33985202-4B2C2C5F-C401-4F19-80C8-1D3269628481 Q36032244-30C69ED7-8F9F-4508-83D3-1312A8A5BFB3 Q37162662-A1BB0627-0BB8-4CC0-B342-2A3393EAC2F7 Q37440263-82AEAE9A-ED19-4660-9A88-25971D52E3F1 Q39061148-000464BD-24B6-442E-84CA-ABED03AEED6E Q44135797-F3637CA1-B515-48B2-8108-F87759B431CB Q46294733-9EE8D2CC-1F31-479A-943B-6D8172D75481 Q47186214-FF3E4C79-4249-453C-B1E4-345B9FC6050E Q52381624-2D4F6321-1E12-4F1D-A2E1-584A75CD6D56

P2860

Development of flexible-heteroarotinoids for kidney cancer

http://www.wikidata.org/entity/Q33926659

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Development of flexible-heteroarotinoids for kidney cancer

@ast

Development of flexible-heteroarotinoids for kidney cancer

@en

type

label

Development of flexible-heteroarotinoids for kidney cancer

@ast

Development of flexible-heteroarotinoids for kidney cancer

@en

prefLabel

Development of flexible-heteroarotinoids for kidney cancer

@ast

Development of flexible-heteroarotinoids for kidney cancer

@en

P1433

Q33926659-5B39CB94-1126-44AE-BBAF-3F27A86B88A4

P1476

Q33926659-BEC0B83D-92A5-45A9-9E45-60CF0F6A8693

P2093

Q33926659-01AD7087-5B7E-4F91-91E9-4B7D1767B820

Q33926659-3ACB76DD-2766-49B6-B78A-4C298EDD5425

Q33926659-74F51685-20DE-4860-AA40-61945D5422FC

Q33926659-9009E9E4-C4D0-4B30-8381-9D8F9C6FE0C6

Q33926659-D6CD43C3-F459-4031-80E9-7540A856ABE7

Q33926659-E3CA45A3-D73F-4DD7-AA1A-C81C72DFF307

Q33926659-E61358C1-F612-439A-8E08-525208627ECC

P2860

Q33926659-14A83594-E09A-4328-82E3-2B20DBCEA33A

Q33926659-16C118CE-C6B3-4C4D-8014-6DEC18D336F8

Q33926659-1EE9A1FE-B5CA-4F87-B37D-6283E93C0C69

Q33926659-20569BE8-FDEF-4BE6-AC86-AC8838A5299C

Q33926659-227E216A-95A6-4298-81C2-C948D074A53D

Q33926659-282CE463-C9A7-4173-8DF1-E45B32D451FD

Q33926659-2A12B2CD-89F9-4AFF-AEF7-EF11D485BBAB

Q33926659-2F2C5CFB-325A-48F1-B2B0-69F8D0860620

Q33926659-37DF4F2A-0F7A-4F35-9909-D74A7F99F9FC

Q33926659-3B650EF4-6318-4B20-A5CF-B4E843C27472

P304

Q33926659-A76AE091-EE41-4EBE-AA7E-1B743349E3EB

P31

Q33926659-4C3A400F-05A2-4819-95E5-DE652C7DB453

P356

Q33926659-865766E0-F7C5-48F4-82F8-80B3C244F979

P433

Q33926659-F7580E6F-0121-48B5-9B19-71844E6347F2

P478

Q33926659-2B70B4A0-FDB3-4735-A956-87E9C7353150

P577

Q33926659-FF2568D2-3A27-4001-9A32-21ACF17D3F5F

P5875

Q33926659-871C9518-1586-466E-A806-E5E1CF14217A

P698

Q33926659-08C32344-E0B6-424C-B8FD-57BB7BC5C76B

P932

Q33926659-1AB8F5FA-7111-48CF-A22E-C6DEE5BAF9D6

P356

1535-7163.MCT-08-1069

P1433

Molecular Cancer Therapeutics

P1476

Development of flexible-heteroarotinoids for kidney cancer

@en

P2093

Chioniso Patience Masamha

http://www.w3.org/2001/XMLSchema#string

Doris Mangiaracina Benbrook

http://www.w3.org/2001/XMLSchema#string

Feng He

http://www.w3.org/2001/XMLSchema#string

K Darrell Berlin

http://www.w3.org/2001/XMLSchema#string

Shylet Chengedza

http://www.w3.org/2001/XMLSchema#string

Stan Lightfoot

http://www.w3.org/2001/XMLSchema#string

Tongzu Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.

E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas.

The changing natural history of renal cell carcinoma.

Recent advances in kidney cancer and metastatic disease.

Evidence that reactive oxygen species do not mediate NF-kappaB activation.

Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis.

Application of retinoids in the treatment of renal cell carcinoma--a futile effort?

N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency

P304

1227-1238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-08-1069

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24403365

http://www.w3.org/2001/XMLSchema#string

P698

19417155

http://www.w3.org/2001/XMLSchema#string

P932

2888972

http://www.w3.org/2001/XMLSchema#string